- One casualty as Takeda refocuses vaccine priorities
- India staring at antibiotic resistance nightmare scenario?
- CureVac propels cancer vaccine in $601m Boehringer Ingelheim deal
- US Capitol Capsule: 'Cures' ain't law yet: Senate concurrence may be tricky
ANALYSIS Other Informa Analysis
COMMENT Other Informa Comment
- 5 questions for Janssen India's boss on TB research and Sirturo
- How patients are helping Scotland say yes to more medicines